Targeted Genetics Sells AAV, Manufacturing Tech to Genzyme for $7M | GenomeWeb

Just days after it was poised to run out of cash, Targeted Genetics last week announced that it has sold its manufacturing and adeno-associated viral vector technologies, among other assets, to Genzyme for up to $7 million.

The transaction, which will enable the company to continue operations through 2010, will transfer Targeted Genetics’ patents, manufacturing-related equipment, and licenses to use certain technology and materials necessary for manufacturing AAV vectors to Genzyme, according to the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.